Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.
Chen L, Mao W, Ren C, Li J, Zhang J.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.3c01802 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
25 träffarDiscovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.
Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.
Garrido A, Vera G, Delaye PO, Enguehard-Gueiffier C.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113867Optimization of 4,6-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth.
Han Y, Zhang H, Wang S, Li B, Xing K, Shi Y, Cao H, Zhang J, Tong T, Zang J, Guan L, Gao X, Wang Y, Liu D, Huang M, Jing Y, Zhao L.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.1c01084Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.
Clin Epigenetics · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13148-021-01037-1Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
Quevedo CE, Bataille CJR, Byrne S, Durbin M, Elkins J, Guillermo A, Jones AM, Knapp S, Nadali A, Walker RG, Wilkinson IVL, Wynne GM, Davies SG, Russell AJ.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2020.115724Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L, Tong R, Yu J, Shi J.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2019.06.002PIM kinase inhibitors: Structural and pharmacological perspectives.
Asati V, Mahapatra DK, Bharti SK.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2019.03.050Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.02.022Targeting the immunity protein kinases for immuno-oncology.
Yuan X, Wu H, Bu H, Zhou J, Zhang H.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.11.072Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN, Hong VS, Lee A, Park J, Kim S, Lee J.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2018.05.054The target landscape of clinical kinase drugs.
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.
Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368Structure based drug design of Pim-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors.
Swellmeen L, Shahin R, Al-Hiari Y, Alamiri A, Hasan A, Shaheen O.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2017.07.036Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.
Nakano H, Hasegawa T, Kojima H, Okabe T, Nagano T.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.6b00518Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Bataille CJ, Brennan MB, Byrne S, Davies SG, Durbin M, Fedorov O, Huber KV, Jones AM, Knapp S, Liu G, Nadali A, Quevedo CE, Russell AJ, Walker RG, Westwood R, Wynne GM.
Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2017.02.056Recent Advances in Scaffold Hopping.
Hu Y, Stumpfe D, Bajorath J.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.6b01437Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K, Li Y, Zhou D, Fan Y, Guo H, Ma T, Wen J, Liu D, Zhao L.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2016.03.016Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.
Fan YB, Li K, Huang M, Cao Y, Li Y, Jin SY, Liu WB, Wen JC, Liu D, Zhao LX.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2016.01.032Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M, Muller K, Bellamacina C, Lindvall MK, Zang R, Huh K, Feucht P, Zavorotinskaya T, Dai Y, Basham S, Chan J, Ginn E, Aycinena A, Holash J, Castillo J, Langowski JL, Wang Y, Chen MY, Lambert A, Fritsch C, Kauffmann A, Pfister E, Vanasse KG, Garcia PD.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.5b01275Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.
Xu Y, Brenning BG, Kultgen SG, Foulks JM, Clifford A, Lai S, Chan A, Merx S, McCullar MV, Kanner SB, Ho KK.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml500300cStructure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Burger MT, Han W, Lan J, Nishiguchi G, Bellamacina C, Lindval M, Atallah G, Ding Y, Mathur M, McBride C, Beans EL, Muller K, Tamez V, Zhang Y, Huh K, Feucht P, Zavorotinskaya T, Dai Y, Holash J, Castillo J, Langowski J, Wang Y, Chen MY, Garcia PD.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml400307jIdentification of potent Yes1 kinase inhibitors using a library screening approach.
Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
Bioorg Med Chem Lett · research support, n.i.h., intramural; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmcl.2013.05.072Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Drygin D, Haddach M, Pierre F, Ryckman DM.
J Med Chem · journal article · DOI 10.1021/jm3009234Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H, Saito N, Parker L, Tada Y, Abe M, Tsuganezawa K, Yokoyama S, Tanaka A, Kojima H, Okabe T, Nagano T.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm3001289Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2011.12.130